Metaiodobenzylguanidine (MIBG) was developed initially as a tracer for oncological imaging; when labeled with 123 I or 131 I, it may detect APUDomas, such as pheochromocytomas and paragangliomas. In the last years, MIBG has found an important role also in neurology and cardiology, as cardiac innervation tracer. Actually, MIBG cardiac imaging is a universally accepted method to estimate cardiac sympathetic innervations. This review covers the role of MIBG cardiac imaging in Parkinson disease and parkinsonisms, from the pathophysiological premises for cardiac denervation to new emerging data.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1701/1315.14575 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic Efficacy of Iodo-Metaiodobenzylguanidine SPECT/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and α-Synucleinopathies.
Diagnostics (Basel)
December 2024
Department of Medicine I, University Hospital Munich, Ludwig-Maximilians-University, 81377 Munich, Germany.
: Iodo-metaiodobenzylguanidine single photon emission computed tomography/computed tomography (I-MIBG SPECT/CT) is used to evaluate the cardiac sympathetic nervous system in cardiac diseases such as arrhythmogenic right ventricular cardiomyopathy (ARVC) and α-synucleinopathies such as Parkinson's diseases. A common feature of these diseases is denervation. We aimed to compare quantitative and semi-quantitative cardiac sympathetic innervation using I-MIBG imaging of ARVC and α-synucleinopathies.
View Article and Find Full Text PDFIodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review.
Pharmaceuticals (Basel)
November 2024
Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100233, Taiwan.
Iodine-123 metaiodobenzylguanidine (I-123 MIBG) is a crucial radiopharmaceutical widely used in nuclear medicine for its diagnostic capabilities in both cardiology and oncology. This review aims to present a comprehensive evaluation of the clinical applications of I-123 MIBG, focusing on its use in diagnosing and managing various diseases. In cardiology, I-123 MIBG has proven invaluable in assessing cardiac sympathetic innervation, particularly in patients with heart failure, where it provides prognostic information that guides treatment strategies.
View Article and Find Full Text PDFGastric emptying time and its correlation with cardiac MIBG in body-first and brain-first subtype Parkinson's disease.
J Neurol
December 2024
Department of Neurology, Ajou University School of Medicine, Suwon, Republic of Korea.
Introduction: Recently, "body-first" and "brain-first" subtype in Parkinson's disease (PD) was proposed based on the propagation of α-synuclein. In isolated RBD considered as a premotor stage of body-first PD, α-synuclein was supposed to originate in the enteric nervous system and spreads via autonomic nervous system. Therefore, we hypothesized that body-first PD is more likely to have a delayed gastric emptying time and reduced cardiac sympathetic denervation.
View Article and Find Full Text PDFComparison of MIBG uptake in the major salivary glands between Lewy body disease and progressive supranuclear palsy.
Clin Park Relat Disord
November 2024
Department of Neurology, Toho University Faculty of Medicine, Tokyo, Japan.
Introduction: Cardiac sympathetic denervation is specific to Lewy body disease (LBD). In Parkinson's disease (PD), sympathetic denervation in the major salivary glands (parotid glands [PG] and submandibular glands [SMG]) has been demonstrated by I-metaiodobenzylguanidine (MIBG) scintigraphy. We compared sympathetic denervation in the MSG between PD, dementia with Lewy bodies (DLB), and progressive supranuclear palsy (PSP).
View Article and Find Full Text PDFEffectiveness of Lee Silverman Voice Treatment (LSVT-LOUD) in Parkinsonian-Type Multiple System Atrophy (MSA-P): A Case Report.
Cureus
November 2024
Graduate School of Health Science, Fukui Health Science University, Fukui, JPN.
Article Synopsis
- A 73-year-old patient with Parkinsonian-type multiple system atrophy (MSA-P) experienced motor symptoms, including gait disturbances and swallowing difficulties, prompting medical evaluation.
- Brain imaging and diagnostic tests confirmed MSA-P, but traditional Parkinson’s treatments showed minimal effectiveness as the patient's condition worsened.
- After undergoing Lee Silverman Voice Treatment (LSVT-LOUD) at age 75, the patient showed significant improvements in speech volume, swallowing abilities, and cognitive function, indicating potential benefits of LSVT-LOUD for patients with MSA-P.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!